Syngen Biotech Statistics

Total Valuation

Syngen Biotech has a market cap or net worth of TWD 3.44 billion. The enterprise value is 3.50 billion.

Market Cap	3.44B
Enterprise Value	3.50B

Important Dates

The last earnings date was Friday, March 7, 2025.

Earnings Date	Mar 7, 2025
Ex-Dividend Date	Jun 27, 2024

Share Statistics

Syngen Biotech has 27.10 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	27.10M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+0.06%
Owned by Insiders (%)	8.15%
Owned by Institutions (%)	4.21%
Float	10.54M

Valuation Ratios

The trailing PE ratio is 14.35.

PE Ratio	14.35
Forward PE	n/a
PS Ratio	1.71
PB Ratio	1.54
P/TBV Ratio	1.56
P/FCF Ratio	11.96
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.48, with an EV/FCF ratio of 12.15.

EV / Earnings	14.56
EV / Sales	1.74
EV / EBITDA	8.48
EV / EBIT	11.74
EV / FCF	12.15

Financial Position

The company has a current ratio of 2.22, with a Debt / Equity ratio of 0.18.

Current Ratio	2.22
Quick Ratio	1.47
Debt / Equity	0.18
Debt / EBITDA	0.95
Debt / FCF	1.38
Interest Coverage	32.70

Financial Efficiency

Return on equity (ROE) is 11.00% and return on invested capital (ROIC) is 7.15%.

Return on Equity (ROE)	11.00%
Return on Assets (ROA)	6.12%
Return on Invested Capital (ROIC)	7.15%
Return on Capital Employed (ROCE)	11.83%
Revenue Per Employee	8.15M
Profits Per Employee	972,498
Employee Count	247
Asset Turnover	0.65
Inventory Turnover	3.71

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -19.62% in the last 52 weeks. The beta is 0.44, so Syngen Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.44
52-Week Price Change	-19.62%
50-Day Moving Average	127.31
200-Day Moving Average	137.06
Relative Strength Index (RSI)	47.64
Average Volume (20 Days)	9,219

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Syngen Biotech had revenue of TWD 2.01 billion and earned 240.21 million in profits. Earnings per share was 8.85.

Revenue	2.01B
Gross Profit	723.94M
Operating Income	303.30M
Pretax Income	299.61M
Net Income	240.21M
EBITDA	402.10M
EBIT	303.30M
Earnings Per Share (EPS)	8.85

Full Income Statement

Balance Sheet

The company has 341.93 million in cash and 397.93 million in debt, giving a net cash position of -56.00 million or -2.07 per share.

Cash & Cash Equivalents	341.93M
Total Debt	397.93M
Net Cash	-56.00M
Net Cash Per Share	-2.07
Equity (Book Value)	2.24B
Book Value Per Share	82.51
Working Capital	634.89M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 348.04 million and capital expenditures -60.21 million, giving a free cash flow of 287.83 million.

Operating Cash Flow	348.04M
Capital Expenditures	-60.21M
Free Cash Flow	287.83M
FCF Per Share	10.62

Full Cash Flow Statement

Margins

Gross margin is 35.95%, with operating and profit margins of 15.06% and 11.93%.

Gross Margin	35.95%
Operating Margin	15.06%
Pretax Margin	14.88%
Profit Margin	11.93%
EBITDA Margin	19.97%
EBIT Margin	15.06%
FCF Margin	14.29%

Dividends & Yields

This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 3.94%.

Dividend Per Share	5.00
Dividend Yield	3.94%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	56.41%
Buyback Yield	n/a
Shareholder Yield	3.94%
Earnings Yield	6.98%
FCF Yield	8.36%

Dividend Details

Stock Splits

The last stock split was on July 9, 2018. It was a forward split with a ratio of 1.1.

Last Split Date	Jul 9, 2018
Split Type	Forward
Split Ratio	1.1

Scores

Syngen Biotech has an Altman Z-Score of 4.63.

Altman Z-Score	4.63
Piotroski F-Score	n/a